Development of vaccine anti-SARS-CoV-2 based on VLPs

• Grant number: 20/05146-7
• Support Opportunities: Regular Research Grants
• Duration: May 01, 2020 - April 30, 2023
• Field of knowledge: Biological Sciences - Immunology - Applied Immunology
• Principal Investigator: Gustavo Cabral de Miranda
• Grantee: Gustavo Cabral de Miranda
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Edecio Cunha Neto ; Jorge Elias Kalil Filho ; Keity Souza Santos
• Associated research grant: 19/14526-0 - Development of vaccines against Streptococcus pyogenes and Chikungunya Virus based on virus like particles, AP.JP
• Associated scholarship(s): 20/09404-0 - Development of vaccine anti-SARS-CoV-2 based on VLPs, BP.PD

Abstract

The emerging SARS-CoV-2 virus appeared in China and easily spread around the world with a tremendous lethality. In less than three months of its identification, it has already caused more than 30,000 deaths worldwide with an increasing number of fatalities. As it is a new virus introduced into the human population, therefore there is no prior immunity; it has easy spread and lethality varies from 1 to 16% according to country, age group and comorbidities. In the absence of a specific vaccine or treatment, the pandemic is paralyzing entire continents. In this project, we aim to use the vaccine platform based on VLPs (virus-like particles) conjugating peptide sequences from SARS-CoV-2 to Q²VLPs and VP1VLPs. The choosen antigen is the the Spike protein from the SARS-CoV-2, and make this VLPs as an antigen delivering to the components of the immune system cells. It is worth to mention that this project was quickly adapted for the development of an effective and safe vaccine against SARS-CoV2 to the JP project, Process number: 2019/14526-0. Because of this, we are already working on selecting the best antigens to be combined with VLPs due to the enormous urgency that this historic moment demands of us. (AU)

Scientific publications

(5)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SADRAEIAN, MOHAMMAD; PINTO JUNIOR, FABIO FRANCISCO; MIRANDA, MARCELA; GALINSKAS, JULIANA; FERNANDES, RAFAELA SACHETTO; DA CRUZ, EDGAR FERREIRA; FU, LIBING; ZHANG, LE; DIAZ, RICARDO SOBHIE; CABRAL-MIRANDA, GUSTAVO; et al. Study of Viral Photoinactivation by UV-C Light and Photosensitizer Using a Pseudotyped Model. PHARMACEUTICS, v. 14, n. 3, p. 15-pg., 2022-03-01. (17/10910-5, 13/07276-1, 19/14526-0, 20/05146-7)

VUITIKA, LARISSA; PRATES-SYED, WASIM A.; QUEIROS SILVA, JAQUELINE DINIS; CREMA, KARIN P.; CORTES, NELSON; LIRA, ALINE; MENUCI LIMA, JULIA BEATRIZ; SARAIVA CAMARA, NIELS OLSEN; SCHIMKE, LENA F.; CABRAL-MARQUES, OTAVIO; et al. Vaccines against Emerging and Neglected Infectious Diseases: An Overview. VACCINES, v. 10, n. 9, p. 11-pg., 2022-09-01. (20/05146-7, 19/14526-0)

CABRAL-MARQUES, OTAVIO; MOLL, GUIDO; CATAR, RUSAN; PREUSS, BEATE; BANKAMP, LUKAS; PECHER, ANN-CHRISTIN; HENES, JOERG; KLEIN, REINHILD; KAMALANATHAN, A. S.; AKBARZADEH, REZA; et al. Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium. AUTOIMMUNITY REVIEWS, v. 22, n. 5, p. 14-pg., 2023-03-14. (18/18886-9, 20/16246-2, 20/01688-0, 20/07069-0, 20/07972-1, 20/05146-7, 19/14526-0)

PRATES-SYED, WASIM A.; CHAVES, LORENA C. S.; CREMA, KARIN P.; VUITIKA, LARISSA; LIRA, ALINE; CORTES, NELSON; KERSTEN, VICTOR; GUIMARAES, FRANCISCO E. G.; SADRAEIAN, MOHAMMAD; BARROSO DA SILVA, FERNANDO L.; et al. LP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variant. VACCINES, v. 9, n. 12, DEC 2021. (20/05146-7, 20/07158-2, 17/10910-5, 19/14526-0)

FREITAS, ISRAELLE NETTO; DA SILVA JR, JOEL ALVES; DE OLIVEIRA, KENIA MORENO; ALVES, BRUNA LOURENCONI; ARAUJO, THIAGO DOS REIS; CAMPOREZ, JOAO PAULO; CARNEIRO, EVERARDO MAGALHAES; DAVEL, ANA PAULA. Insights by which TUDCA is a potential therapy against adiposity. FRONTIERS IN ENDOCRINOLOGY, v. 14, p. 8-pg., 2023-02-21. (18/26080-4, 20/05146-7, 19/15164-5)